Results 121 to 130 of about 29,889 (292)

FVIIIa Mimetics: New Approaches and Next‐Generation Initiatives

Haemophilia, EarlyView.
ABSTRACT Emicizumab has revolutionized hemophilia A care, yet limitations regarding the “ceiling” of hemostatic efficacy (equivalent to mild hemophilia) and global access persist. This review critically examines two distinct paradigms shaping the future of care: Innovation and Access. Regarding innovation, we synthesize the latest clinical data on next‐
Tadashi Matsushita, Keiji Nogami, Chandrakala Shanmukhaiah   +2 more
wiley   +1 more source

Data for: Data from differentially expressed proteins in platelet components associated with adverse transfusion reactions.

, 2019
These data correspond to the processing data obtained from protein differentially expression analysis of blood platelet components (PCs), when those PCs were found in association with adverse transfusion reactions (ATRs), in the following types: i ...
Aloui, C (via Mendeley Data)
core   +1 more source

Gene Editing for Haemophilia—The Next Frontier

Haemophilia, EarlyView.
ABSTRACT The recently approved haemophilia A and B gene therapies via adeno‐associated virus (AAV) showed a promising therapeutic response after a single injection, but there are still limitations, including the potential loss of transgene expression and restriction in adults.
Mirko Pinotti, Gregory A. Newby, Sundar Selvaraj, Steven W. Pipe   +3 more
wiley   +1 more source

Real‐World Use of Emicizumab in Patients With Acquired Haemophilia A: An Interim Safety Analysis of a Large‐Scale Post‑Marketing Surveillance Study

Haemophilia, EarlyView.
ABSTRACT Introduction Acquired haemophilia A (AHA) is a rare autoimmune disorder where the development of autoantibodies to factor (F)VIII neutralise its function, leading to bleeding. Emicizumab has been approved for treating AHA in Japan. Aim This post‐marketing study was performed to primarily examine the use and safety of emicizumab, and indirectly
Midori Shima, Katsuyuki Fukutake, Yoshiyuki Ogawa, Yuta Kamei, Chiaki Sugita, Akinori Yuri, Ryota Kobayashi, Akiko Ioka, Tadashi Matsushita   +8 more
wiley   +1 more source

Pilot study to understand and compare challenges being faced in reporting of transfusion reactions in various types of blood banks enrolled under Haemovigilance Programme of India

Asian Journal of Transfusion Science
BACKGROUND: Hemovigilance has become one of the important quality check systems of blood transfusion process, but under/non-reporting of transfusion-associated adverse reactions despite the presence of reporting systems emphasize the need to understand ...
Rayaz Ahmad Bhat, Vishal Tiwari, Satyajeet Singh, Ruchi Rao, Akash Chaudhary, Akanksha Bisht   +5 more
doaj   +1 more source

Effects of Adipose Plasma Transfusion Compared with Normal Plasma Transfusion on Adverse Transfusion Reactions, Important Functional Indicators, and Clinical Safety in Patients with Parenteral Nutrition: Based on a Retrospective Cohort Study.

Evid Based Complement Alternat Med, 2022
Gong C, Qin X, Chen H, Wu X, Wu J, Li H, Wang W.   +6 more
europepmc   +1 more source

Perioperative Outcomes in Factor XI Deficiency: A Systematic Review

Haemophilia, EarlyView.
ABSTRACT Background Congenital factor XI (FXI) deficiency has a variable bleeding phenotype, and FXI activity alone does not predict perioperative bleeding. Management practices remain heterogeneous, and available evidence derives from case reports, small case series, and retrospective cohorts.
Zainab Al‐Housni, Raeesah Mohammed, Silvio Ligia, Jim Douketis, Chatree Chai‐Adisaksopha, Alfonso Iorio, Davide Matino   +6 more
wiley   +1 more source

Management of Breakthrough Bleeding During Emicizumab Prophylaxis in Acquired Haemophilia A: Data From the GTH‐AHA‐EMI Study

Haemophilia, EarlyView.
ABSTRACT Introduction The GTH‐AHA‐EMI study showed that emicizumab reduces bleeding in patients with acquired haemophilia A (AHA). However, 22 clinically relevant new bleeds (CRNB) occurred in 14 of the 47 study patients, most of which required haemostatic treatment.
Halet Türkantoz, Christiane Dobbelstein, Richard Greil, Christina Hart, Robert Klamroth, Paul Knöbl, Johannes Oldenburg, Christian Pfrepper, Ulrich Sachs, Inga M. Schimansky, Karolin Trautmann‐Grill, Andreas Tiede   +11 more
wiley   +1 more source

Adverse transfusion reactions following transfusion of blood and blood products in a tertiary care hospital: A step toward hemovigilance

Background: Transfusion of blood and blood products is a double-edged sword, so it should be used judiciously. The primary aim of the centralized hemovigilance program is to improve transfusion safety.
Zarika Ahmed, Mrigen Choudhury, Aparna Dutta, Adity Sharma   +3 more
core   +1 more source

Lack of association between vaccine‐induced immune thrombocytopenia and thrombosis and HLA loci in a large cohort

British Journal of Haematology, EarlyView.
Linda Schönborn, Ana Tzvetkova, Thomas Thiele, Uwe Völker, Sabine Ameling, Sören Franzenburg, Lars Kaderali, Andreas Greinacher   +7 more
wiley   +1 more source